WNT3A and persistent truncus arteriosus: Moreover, by integrating network pharmacology and experimental investigations, we have uncovered that a natural compound, MAT, possesses the capability to inhibit the Wnt3a/β‐catenin signalling pathway, thereby attenuating atrial fibrosis and inflammatory responses, ultimately reducing the incidence of TAC‐induced AF (Figure 7S).